ID: h-5044496a
Hypothesis
DNMT1 Downregulation to Correct Genome-Wide Hypomethylation
DNMT1 Downregulation to Correct Genome-Wide Hypomethylation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
DNMT1 Downregulation to Correct Genome-Wide Hypomethylation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["DNMT1 Maintenance Methyltransferase<br/>PCNA-Dependent Replication"]
B["Genomic Stability<br/>Centromeric and Pericentromeric Methylation"]
C["DNA Damage Response<br/>Mismatch Repair and CpG Island Maintenance"]
D["Neuronal Epigenetic Memory<br/>Synaptic Gene Silencing"]
E["DNMT1 Deficiency<br/>Global Hypomethylation and Genomic Instability"]
F["DNMT1 Compensation<br/>Synaptic Resilience Gene Reactivation"]
A --> B
B --> C
C --> D
D --> E
F -.->|"counteracts"| E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
DNMT1 activity decreases in AD temporal cortex, correlating with global hypomethylation
Supports
DNMT1 haploinsufficiency in mice shows improved neuronal survival without developmental abnormalities
Contradicts
DNMT1 dysfunction causes hypomethylation - the therapeutic strategy should be DNMT1 activation, not downregulation
Contradicts
Complete DNMT1 loss causes catastrophic genomic instability and cell death - therapeutic window is narrow
Contradicts
DNMT1 inhibitors (azacitidine, decitabine) are used in oncology to cause hypomethylation - opposite of neurodegeneration needs
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — DNMT1
No curated PDB or AlphaFold mapping for DNMT1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for DNMT1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for DNMT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 1.0%
Volatility
Low
0.0082
Events (7d)
3
Price History
▲22.7%💾 Resource Usage
LLM Tokens
34,738
$0.1042
Total Cost
$0.1042
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF AD patients with high baseline DNMT1 expression (top quartile in cerebrospinal fluid mononuclear cells) receive 6-month treatment with DNMT1-lowering intervention (siRNA or small molecule), THEN CS | Cohort receiving DNMT1 modulation will show significant reduction in neuroinflammatory markers and stable or improved cognitive scores versus declining trajecto | — no observation — | pending | 0.40 |
| IF DNMT1 is downregulated (via CRISPRi or pharmacological inhibition) in iPSC-derived neurons from Alzheimer's disease patients for 14-21 days, THEN global DNA methylation levels will increase by ≥15% | Global DNA methylation levels in treated neurons will increase toward age-matched healthy control neuron values, with mean beta values increasing by ≥0.15 from | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF DNMT1 is downregulated (via CRISPRi or pharmacological inhibition) in iPSC-derived neurons from Alzheimer's disease patients for 14-21 days, THEN global DNA methylation levels will increase by ≥15% (measured by reduced variance in beta values toward normal) compared to untreated patient-derived n
Predicted outcome: Global DNA methylation levels in treated neurons will increase toward age-matched healthy control neuron values, with mean beta values increasing by ≥
Falsification: No significant change in global methylation levels (change <5%) or further decrease in methylation following DNMT1 downregulation, indicating failure to correct hypomethylation.
pendingconf 40%
IF AD patients with high baseline DNMT1 expression (top quartile in cerebrospinal fluid mononuclear cells) receive 6-month treatment with DNMT1-lowering intervention (siRNA or small molecule), THEN CSF biomarkers of neuroinflammation (IL-6, TNF-α) will decrease by ≥25% and mini-mental state examinat
Predicted outcome: Cohort receiving DNMT1 modulation will show significant reduction in neuroinflammatory markers and stable or improved cognitive scores versus declinin
Falsification: No change or increase in inflammatory biomarkers, and cognitive scores continue declining at same rate as control group, indicating DNMT1 modulation provides no therapeutic benefit.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.